Sermorelin Peptide Research Hub — GHRH(1-29) Analog Studies
Sermorelin is a synthetic 29-amino-acid fragment of growth hormone releasing hormone (GHRH) — the shortest sequence retaining full GHRH receptor activity. It is one of the most extensively cited GHRH analogues in pulsatile GH release research.
What this hub covers
- GHRH(1-29) sequence and receptor activation
- Pulsatile pituitary GH release vs exogenous somatropin
- Short half-life and DPP-IV cleavage kinetics
- Comparisons to tesamorelin and CJC-1295 (DAC/no-DAC)
- Stacking literature with GHRPs (ipamorelin, hexarelin)
Sermorelin research articles
All research →Sermorelin Research Overview
Sermorelin (GHRH 1–29 NH₂) is a synthetic 29-amino acid analogue of the N-terminal active fragment of endogenous growth hormone-releasing hormone — the foundational GHRH-based research compound that established the pituitary-stimulating approach to GH axis restoration and preceded all subsequent GHRH analogues including Tesamorelin and Modified GRF 1-29.
Read article →Sermorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for sermorelin — the GHRH(1-29) reference peptide and closest pharmacologic proxy to physiologic GH pulses.
Read article →CJC-1295 DAC vs No DAC: Research Overview
A research-context comparison of CJC-1295 with and without the Drug Affinity Complex modification — pharmacokinetics, GH secretion patterns, and the implications for pulsatility.
Read article →Tesamorelin Research Overview
A synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), studied for its role in GH/IGF-1 axis stimulation, visceral adiposity reduction, and metabolic research contexts.
Read article →Tesamorelin Benefits and Side Effects: A Research Guide
Published benefits, side effects, and comparisons for tesamorelin — the GHRH(1-44) analog with the strongest clinical evidence base for visceral-fat reduction.
Read article →HGH vs Peptide-Based GH Stimulation: A Research Comparison
A definitive research comparison of exogenous HGH (somatropin) versus peptide-based GH axis stimulation using GHRH analogues and GHRPs — covering pulsatility, physiological authenticity, IGF-1 profiles, receptor sensitivity, regulatory status, cost, and how to select the right approach for specific research applications.
Read article →Sermorelin research FAQ
- What is sermorelin?
- Sermorelin is a 29-amino-acid peptide corresponding to the first 29 residues of human GHRH — the shortest fragment retaining full receptor binding and pituitary GH-releasing activity in published research models.
- How does sermorelin compare to tesamorelin?
- Both are GHRH analogues, but tesamorelin carries a stabilising trans-3-hexenoyl group that resists DPP-IV cleavage and extends half-life. Sermorelin has a shorter native half-life (~10–20 min) and is used as a closer proxy to physiological GHRH pulses.
- Why is sermorelin paired with ipamorelin in research?
- GHRH analogues and GHRPs act on distinct pituitary pathways. Combining sermorelin (GHRH receptor) with ipamorelin (ghrelin receptor) produces synergistic GH release in published models — see the GHRH/GHRP synergy literature in the featured articles.
- How is sermorelin stored?
- Lyophilized sermorelin is stored at 2–8 °C protected from light; once reconstituted with bacteriostatic water, store refrigerated and use within the COA's documented window.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.